Dianhydrogalactitol
- Generic Name
- Dianhydrogalactitol
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10O4
- CAS Number
- 23261-20-3
- Unique Ingredient Identifier
- 4S465RYF7M
- Background
Dianhydrogalactitol has been used in trials studying the treatment of GBM, Glioma, Glioblastoma, Brain Cancer, and Glioblastoma Multiforme.
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- DelMar Pharmaceuticals, Inc.
- Registration Number
- NCT03281681
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
- Conditions
- Glioblastoma MultiformeGliomaGBMBrain CancerGlioblastoma
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- DelMar Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03149575
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of California, San Francisco - Division of Neuro-Oncology, San Francisco, California, United States
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
- Conditions
- GBMBrain CancerGliomaGlioblastoma MultiformeGlioblastoma
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Kintara Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02717962
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.